We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MKS:LSEMarks and Spencer Group plc Analysis

Data as of 2026-03-14 - not real-time

£358.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Marks & Spencer (MKS.L) is trading at £358.5, sitting below its 20‑day (£383.3) and 50‑day (£372.2) simple moving averages, which signals short‑term weakness. The 14‑day RSI of 38 points places the stock in oversold territory, while the MACD line remains negative and the histogram widens, reinforcing a bearish momentum. Nevertheless, the broader 200‑day SMA (~£359) is almost aligned with the current price, and the chart shows a clear support zone around £347.7, suggesting a floor for downside risk. Volume has been trending lower, indicating waning participation in recent moves.
Fundamentally, the group posted a 22.5 % revenue surge to £15.3 bn, yet profit margins linger at a razor‑thin 0.13 %, driving an astronomical trailing PE of 358.5× while the forward PE contracts to 10.7× on an EPS forecast of £0.34. The discounted cash‑flow model values the shares at roughly £630, implying an 18‑19 % upside from today’s price and supporting an undervalued label. However, a debt‑to‑equity ratio above 110 % and a payout ratio of 400 % render the 1.05 % dividend unsustainable in the near term. Return on equity is virtually nil (0.05 %), underscoring the earnings fragility despite strong top‑line growth.
Analyst consensus remains bullish, with 16 contributors rating the stock a “Buy” and median price targets near £435, aligning with the DCF upside. The market sentiment index sits in “Greed” territory (72.9), reflecting optimism that may be pricing in the anticipated earnings lift. Given the mixed technical signals, elevated leverage, and modest upside, the stock warrants a cautious but positive stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at £347.7
  • Oversold RSI suggesting potential bounce
  • Decreasing volume indicating limited short‑term buying pressure

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF implied fair value of £630 (+18% upside)
  • Strong 22.5% revenue growth
  • Forward PE compression to 10.7× reflecting earnings acceleration

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Analyst consensus of “Buy” with median target £435
  • Brand resilience in consumer cyclical sector
  • Undervalued fundamentals relative to cash‑flow based valuation

Key Metrics & Analysis

Financial Health

Revenue Growth22.50%
Profit Margin0.13%
P/E Ratio358.5
ROE0.05%
ROA2.97%
Debt/Equity114.26
P/B Ratio260.2
Op. Cash Flow£1.1B
Free Cash Flow£450.8M

Technical Analysis

TrendBullish
RSI38.2
Support£347.70
Resistance£410.30
MA 20£383.33
MA 50£372.17
MA 200£359.03
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value£630.33
Target Price£425.31
Upside/Downside18.64%
GradeUndervalued
TypeGrowth
Dividend Yield1.05%

Risk Assessment

Beta-0.06
Volatility29.97%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.